[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625815":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":56,"centralContacts":60,"locations":67,"responsibleParty":86,"collaborators":65,"id":88,"slug":89,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":90,"sex":95,"minAge":96,"maxAge":65,"enrollmentInfo":97,"targetDuration":65,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":108,"overallStatus":70,"whyStopped":65,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"University Hospital, Clermont-Ferrand","OTHER",[8,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Paclitaxel group","EXPERIMENTAL","Patients suffering from lung cancer and treated with paclitaxel",[13,14,15,16,17,18],"Diagnostic Test: Assessment of blood concentrations of microRNAs","Other: Chemotherapy-induced peripheral neuropathy (CIPN) - grade","Other: Pain assessement","Diagnostic Test: Assessment of blood concentrations of neurofilament light chain","Other: Neuropathic pain assessment","Other: Chemotherapy-induced peripheral neuropathy (CIPN) - severity",{"label":20,"type":10,"description":21,"interventionNames":22},"Oxaliplatin group","Patients suffering from colorectal cancer and treated with oxaliplatin",[13,14,15,16,17,18],[24,31,36,41,46,51],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DIAGNOSTIC_TEST","Assessment of blood concentrations of microRNAs","day 1, day 43, and day 155.",[20,9],[30],"MicroRNAs measured in patients' plasma.",{"type":6,"name":32,"description":27,"armGroupLabels":33,"otherNames":34},"Chemotherapy-induced peripheral neuropathy (CIPN) - grade",[20,9],[35],"CIPN grade monitored using the National Cancer Institute - Common Terminology Criteria for Adverse Events.",{"type":6,"name":37,"description":27,"armGroupLabels":38,"otherNames":39},"Pain assessement",[20,9],[40],"Pain assessment done with a numeric rating scale (scores from 0 (best) to 10 (worst)).",{"type":25,"name":42,"description":27,"armGroupLabels":43,"otherNames":44},"Assessment of blood concentrations of neurofilament light chain",[20,9],[45],"Neurofilament light chain will measured in patients' plasma.",{"type":6,"name":47,"description":27,"armGroupLabels":48,"otherNames":49},"Neuropathic pain assessment",[20,9],[50],"Neuropathic pain assessed with the DN4 questionnaire, scores from 0 (best) to 7 (worst), and with a cut-off of 3 on 7 for neuropathic pain screening.",{"type":6,"name":52,"description":27,"armGroupLabels":53,"otherNames":54},"Chemotherapy-induced peripheral neuropathy (CIPN) - severity",[20,9],[55],"CIPN severity assessed with the self-administered questionnaire QLQ-CIPN20 (scores from 0 (best) to 100 (worst)).",[57],{"name":58,"affiliation":5,"role":59},"David BALAYSSAC","PRINCIPAL_INVESTIGATOR",[61],{"name":62,"role":63,"phone":64,"phoneExt":65,"email":66},"Lise Laclautre","CONTACT","334.73.754.963",null,"promo_interne_drci@chu-clermontferrand.fr",[68],{"facility":69,"status":70,"city":71,"state":65,"zip":65,"country":72,"countryCode":73,"cosmosGeoPoint":74,"geoPoint":79,"contacts":80},"CHU Clermont-Ferrand","RECRUITING","Clermont-Ferrand","France","FR",{"type":75,"coordinates":76},"Point",[77,78],3.08682,45.77969,{"lat":78,"lon":77},[81,85],{"name":82,"role":63,"phone":83,"phoneExt":65,"email":84},"Lise LACLAUTRE","0473754963","llaclautre_perrier@chu-clermontferrand.fr",{"name":58,"role":59,"phone":65,"phoneExt":65,"email":65},{"type":87,"investigatorFullName":65,"investigatorTitle":65,"investigatorAffiliation":65,"oldNameTitle":65,"oldOrganization":65},"SPONSOR","100625815","exploration-of-circulating-micrornas-as-biomarkers-of-chemo-induced-peripheral-neuropathy-a-study-in-cancer-patients-100625815",false,"NCT07427537","Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients","miR-CIPN#1","Inclusion Criteria:\n\n* Patient treated for colorectal cancer and scheduled to receive oxaliplatin-based adjuvant chemotherapy for at least 6 cycles, or\n* Patient treated for lung cancer and scheduled to receive paclitaxel-based chemotherapy for at least 4 cycles.\n\nExclusion Criteria:\n\n* Neurodegenerative disease (e.g., Parkinson's, Alzheimer's, etc.),\n* History of stroke,\n* Pre-existing neuropathy (QLQ-CIPN20 sensory score ≥ 15\u002F100),\n* Pain (NRS ≥ 4\u002F10),\n* Pregnant or breastfeeding women,\n* Patients under guardianship, curatorship, deprived of liberty, or under legal protection","ALL","18 Years",{"count":98,"type":99},90,"ESTIMATED","INTERVENTIONAL",[102],"NA","This study aims to find out whether certain molecules in the blood, called microRNAs, are linked to how often and how severely people develop nerve damage from chemotherapy. The investigators will look at patients receiving cancer drugs known to affect the nerves, such as paclitaxel (used for lung cancer) and oxaliplatin (used for colorectal cancer).",[105,106,107],"Cancer, Lung","Colon Neoplasm","Neuropathy;Peripheral",[109,110,111,112,113,114],"biomarker","colorectal cancer","lung cancer","oxaliplatin","paclitaxel","chemotherapy-induced peripheral neuropathy","2026-02-16",{"date":117,"type":118},"2026-02-23","ACTUAL",{"date":120,"type":118},"2026-01-29",{"date":122,"type":99},"2028-07-31",{"name":5,"class":6},1]